Up-till now, a host of pathogenic bacteria have developed increasing resistance towards available antibacterial agents. Recently introduced strategy of targeting two-component signal transduction (TCST) in bacteria is hopefully a success. TCST is the predominant signaling scheme used in bacteria to sense and respond to environmental changes in order to survive and thrive. TCST response regulators that control virulence is a viable strategy for the development of antimicrobial therapeutics with novel modes of action.

Dear Muhammad. Near in the future the bacterial efflux pumps inhibitors will be an adjuvant in antimicrobial chemotherpy. In tuberculosis treatment there is a proposal and results using Thioridazine as efflux pump inhibitor in combination with antibiotics

http://www.ncbi.nlm.nih.gov/pubmed/22353004

http://jac.oxfordjournals.org/content/51/1/9.full

http://www.omicsgroup.org/journals/BCPC/BCPC-1-e102.pdf

With best regards

I think antibiotics still are relevant in the future. And it depends on how you define the term "antibiotic". Multi-prong attack on bacteria would be the best. I like the paper from Fernando Baquero as recommended by Fadi. Baquero has great vision.

Hi Muhammad

Its really a question of which came first! If virulence inhibitors were discovered and researched before antibiotics then you might have been asking the question "Whether Antibiotics will ever replace virulence inhibitors in the near future?"... won't you?

The answer is that humans will use antibiotics and virulence inhibitors; the way it suits them! If a bacteria is resistant to the intended antibiotic then the use of a virulence inhibitor will be "necessary"; on the other hand; if a bacteria dies with the use of an antibiotic then using a virulence inhibitor would be "stupidity" unless the virulence inhibitor has a clear-cut advantage like lesser side-effects, faster effect etc.

Hope this helped. Thanks

Sid

actually i think that antibiotics put a great deal of selective pressure on the target bacterial population not in case of virulence inhibitors like take the example of Augmentin for instance this drug combines an antibiotic and also a beta lactamase inhibitor (virulence inhibitor) I don't know about other countries but in South Asia this formulation is best antibiotic brand is most effective.

http://en.wikipedia.org/wiki/Amoxicillin/clavulanic_acid

That's exactly what I told before: we use them as we see fit! By the way I know very well about Augmentin; made by GSK; contains amoxycillin and potassium clavulanate! It worked wonders for me when I had an acute bacterial infection in my throat! Thank you GSK!

Sid

Maybe the problem with the development of virulence inhibitions is avoid the transformation of an acute disease to chronic disease, because some times the two component system plays between gene expression of virulence factors and/or biofilm formation (i.e. Vibrio cholera)

Virulence inhibitors have many advantages over traditional antibiotics. Virulence inhibitors just target a subset of bacteria, leaving the microbiota intact. As microbiota is critical for host immune system, and metabolism, it's important not to disturb them. In addition, virulence inhibitors disarm pathogens without killing them, thus do not directly select for the resistant bacteria for survival advantage.